Table of Content

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DEMAND FOR NEWBORN SCREENING INSTRUMENTS IS RISING STEADILY
3.2.2. GROWTH IN DRY BLOOD SPOT TEST
3.2.3. TECHNIQUES USED IN NEWBORN SCREENING TESTS

4. MARKET DYNAMICS
4.1. ETYMOLOGY OF NEWBORN SCREENING
4.2. MARKET SCOPE & DEFINITION
4.3. MARKET DRIVERS
4.3.1. INCREASE IN OCCURRENCES OF NEWBORN DISEASES
4.3.2. GROWING NUMBER OF INFANTS WITH BIRTH DEFECT
4.3.3. BACKING OF GOVERNMENT TOWARDS NEWBORN CHILD HEALTH
4.3.4. RISING AWARENESS FOR PEDIATRIC CONGENITAL HEART DISEASE
4.4. MARKET RESTRAINTS
4.4.1. ABSENCE OF PROPER HEALTHCARE INFRASTRUCTURE FOR NEWBORN BABIES IN DEVELOPING COUNTRIES
4.4.2. SOCIO-ECONOMIC HURDLES IN THE IMPLEMENTATION OF NEWBORN CHILD SCREENING
4.5. MARKET OPPORTUNITIES
4.5.1. INCREASING FERTILITY RATES ACROSS THE GLOBE IS CREATING DYNAMIC GROWTH
4.5.2. NEWBORN SCREENING HELPS IN EARLY IDENTIFICATION AND MANAGEMENT OF AFFECTED NEWBORNS
4.5.3. TECHNOLOGICAL ADVANCEMENTS IN NEWBORN SCREENING
4.5.4. INCREASE IN NUMBER OF PREGNANT WOMEN WITH ADVANCED MATERNAL AGE
4.6. MARKET CHALLENGES
4.6.1. DEARTH OF SKILLED PROFESSIONAL IN HEALTHCARE INDUSTRY
4.6.2. MAINTENANCE OF EQUIPMENT IN HOSPITAL

5. MARKET BY PRODUCT
5.1. NEWBORN SCREENING INSTRUMENTS
5.2. NEWBORN SCREENING REAGENTS & ASSAY KITS

6. MARKET BY TEST TYPE
6.1. HEARING SCREEN TEST
6.2. CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST
6.3. DRY BLOOD SPOT TEST

7. MARKET BY TECHNOLOGY
7.1. TANDEM MASS SPECTROMETRY
7.2. PULSE OXIMETRY
7.3. ENZYME BASED ASSAYS
7.4. DNA BASED ASSAYS
7.5. ELECTROPHORESIS
7.6. OTHERS

8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. KEY BUYING CRITERIA
8.2.1. RELIABILITY
8.2.2. COST
8.2.3. AVAILABILITY
8.2.4. TECHNOLOGICAL ADVANCEMENT
8.3. OPPORTUNITY MATRIX
8.4. VENDOR LANDSCAPE
8.5. VALUE CHAIN ANALYSIS
8.5.1. RAW MATERIAL SUPPLIERS
8.5.2. MANUFACTURERS
8.5.3. DISTRIBUTORS
8.5.4. END-USERS
8.6. LEGAL, POLICY & REGULATORY FRAMEWORK

9. EUROPE
9.1. UNITED KINGDOM
9.2. FRANCE
9.3. ITALY
9.4. RUSSIA
9.5. SPAIN
9.6. GERMANY
9.7. REST OF EUROPE

10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. CORPORATE STRATEGIES
10.2.1. PRODUCT LAUNCH
10.3. COMPANY PROFILES
10.3.1. SCIEX
10.3.1.1. OVERVIEW
10.3.1.2. PRODUCT PORTFOLIO
10.3.1.3. STRATEGIC INITIATIVES
10.3.1.4. SCOT ANALYSIS
10.3.2. BIOTEK INSTRUMENTS INC.
10.3.2.1. OVERVIEW
10.3.2.2. PRODUCT PORTFOLIO
10.3.2.3. STRATEGIC INITIATIVES
10.3.2.4. SCOT ANALYSIS
10.3.3. BIO-RAD LABORATORIES INC.
10.3.3.1. OVERVIEW
10.3.3.2. PRODUCT PORTFOLIO
10.3.3.3. STRATEGIC INITIATIVES
10.3.3.4. SCOT ANALYSIS
10.3.4. CARDINAL HEALTH INC.
10.3.4.1. OVERVIEW
10.3.4.2. PRODUCT PORTFOLIO
10.3.4.3. STRATEGIC INITIATIVES
10.3.4.4. SCOT ANALYSIS
10.3.5. GE HEALTHCARE LIMITED
10.3.5.1. OVERVIEW
10.3.5.2. PRODUCT PORTFOLIO
10.3.5.3. STRATEGIC INITIATIVES
10.3.5.4. SCOT ANALYSIS
10.3.6. AGILENT TECHNOLOGIES INC.
10.3.6.1. OVERVIEW
10.3.6.2. PRODUCT PORTFOLIO
10.3.6.3. STRATEGIC INITIATIVES
10.3.6.4. SCOT ANALYSIS
10.3.7. MASIMO CORPORATION
10.3.7.1. OVERVIEW
10.3.7.2. PRODUCT PORTFOLIO
10.3.7.3. STRATEGIC INITIATIVES
10.3.7.4. SCOT ANALYSIS
10.3.8. NATUS MEDICAL INCORPORATED
10.3.8.1. OVERVIEW
10.3.8.2. PRODUCT PORTFOLIO
10.3.8.3. STRATEGIC INITIATIVES
10.3.8.4. SCOT ANALYSIS
10.3.9. MEDTRONIC PLC
10.3.9.1. OVERVIEW
10.3.9.2. PRODUCT PORTFOLIO
10.3.9.3. STRATEGIC INITIATIVES
10.3.9.4. SCOT ANALYSIS
10.3.10. THERMO FISHER SCIENTIFIC INC.
10.3.10.1. OVERVIEW
10.3.10.2. PRODUCT PORTFOLIO
10.3.10.3. STRATEGIC INITIATIVES
10.3.10.4. SCOT ANALYSIS
10.3.11. NEOGEN LABS PVT. LTD.
10.3.11.1. OVERVIEW
10.3.11.2. PRODUCT PORTFOLIO
10.3.11.3. STRATEGIC INITIATIVES
10.3.11.4. SCOT ANALYSIS
10.3.12. PERKINELMER INC.
10.3.12.1. OVERVIEW
10.3.12.2. PRODUCT PORTFOLIO
10.3.12.3. STRATEGIC INITIATIVES
10.3.12.4. SCOT ANALYSIS
10.3.13. ZENTECH S.A.
10.3.13.1. OVERVIEW
10.3.13.2. PRODUCT PORTFOLIO
10.3.13.3. STRATEGIC INITIATIVES
10.3.13.4. SCOT ANALYSIS
10.3.14. WATERS CORPORATION
10.3.14.1. OVERVIEW
10.3.14.2. PRODUCT PORTFOLIO
10.3.14.3. STRATEGIC INITIATIVES
10.3.14.4. SCOT ANALYSIS
10.3.15. TRIVITRON HEALTHCARE
10.3.15.1. OVERVIEW
10.3.15.2. PRODUCT PORTFOLIO
10.3.15.3. STRATEGIC INITIATIVES
10.3.15.4. SCOT ANALYSIS

List of Tables
TABLE 1. EUROPE NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2. EUROPE INCIDENCE OF CHROMOSOMAL ABNORMALITIES IN NEWBORNS
TABLE 3. INFANT MORTALITY RATE IN DEVELOPING COUNTRIES (TOTAL DEATH/ 1000 LIVE BIRTHS)
TABLE 4. EUROPE NEWBORN SCREENING MARKET, BY PRODUCT, 2019-2027, (IN $ MILLION)
TABLE 5. EUROPE NEWBORN SCREENING MARKET, BY TEST TYPE, 2019-2027, (IN $ MILLION)
TABLE 6. EUROPE NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2019-2027, (IN $ MILLION)
TABLE 7. OPPORTUNITY MATRIX
TABLE 8. VENDOR LANDSCAPE
TABLE 9. REGULATORY FRAMEWORK
TABLE 10. EUROPE NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)
TABLE 11. LIST OF PRODUCT LAUNCHES

List of Figures
FIGURE 1. EUROPE NEWBORN SCREENING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018 & 2027 (IN %)
FIGURE 2. CAUSES OF DEATH AMONG NEWBORNS EUROPE (0-27 DAYS)
FIGURE 3. FERTILITY RATE (AVERAGE BIRTHS PER WOMAN IN %) 2017
FIGURE 4. EUROPE NEWBORN SCREENING MARKET, BY NEWBORN SCREENING INSTRUMENTS, 2019-2027 (IN $ MILLION)
FIGURE 5. EUROPE NEWBORN SCREENING MARKET, BY NEWBORN SCREENING REAGENTS & ASSAY KITS, 2019-2027 (IN $ MILLION)
FIGURE 6. EUROPE NEWBORN SCREENING MARKET, BY HEARING SCREEN TEST, 2019-2027 (IN $ MILLION)
FIGURE 7. EUROPE NEWBORN SCREENING MARKET, BY CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST, 2019-2027 (IN $ MILLION)
FIGURE 8. EUROPE NEWBORN SCREENING MARKET, BY DRY BLOOD SPOT TEST, 2019-2027 (IN $ MILLION)
FIGURE 9. EUROPE NEWBORN SCREENING MARKET, BY TANDEM MASS SPECTROMETRY, 2019-2027 (IN $ MILLION)
FIGURE 10. EUROPE NEWBORN SCREENING MARKET, BY PULSE OXIMETRY, 2019-2027 (IN $ MILLION)
FIGURE 11. EUROPE NEWBORN SCREENING MARKET, BY ENZYME BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 12. EUROPE NEWBORN SCREENING MARKET, BY DNA BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 13. EUROPE NEWBORN SCREENING MARKET, BY ELECTROPHORESIS, 2019-2027 (IN $ MILLION)
FIGURE 14. EUROPE NEWBORN SCREENING MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 15. PORTER’S FIVE FORCE ANALYSIS
FIGURE 16. KEY BUYING IMPACT ANALYSIS
FIGURE 17. VALUE CHAIN ANALYSIS
FIGURE 18. EUROPE NEWBORN SCREENING MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 19. UNITED KINGDOM NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 20. FRANCE NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 21. ITALY NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 22. RUSSIA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 23. SPAIN NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 24. GERMANY NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 25. REST OF EUROPE NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 26. INDUSTRY PLAYER POSITIONING IN 2018 (IN %)



List of Figures


FIGURE 1. EUROPE NEWBORN SCREENING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018 & 2027 (IN %)
FIGURE 2. CAUSES OF DEATH AMONG NEWBORNS EUROPE (0-27 DAYS)
FIGURE 3. FERTILITY RATE (AVERAGE BIRTHS PER WOMAN IN %) 2017
FIGURE 4. EUROPE NEWBORN SCREENING MARKET, BY NEWBORN SCREENING INSTRUMENTS, 2019-2027 (IN $ MILLION)
FIGURE 5. EUROPE NEWBORN SCREENING MARKET, BY NEWBORN SCREENING REAGENTS & ASSAY KITS, 2019-2027 (IN $ MILLION)
FIGURE 6. EUROPE NEWBORN SCREENING MARKET, BY HEARING SCREEN TEST, 2019-2027 (IN $ MILLION)
FIGURE 7. EUROPE NEWBORN SCREENING MARKET, BY CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST, 2019-2027 (IN $ MILLION)
FIGURE 8. EUROPE NEWBORN SCREENING MARKET, BY DRY BLOOD SPOT TEST, 2019-2027 (IN $ MILLION)
FIGURE 9. EUROPE NEWBORN SCREENING MARKET, BY TANDEM MASS SPECTROMETRY, 2019-2027 (IN $ MILLION)
FIGURE 10. EUROPE NEWBORN SCREENING MARKET, BY PULSE OXIMETRY, 2019-2027 (IN $ MILLION)
FIGURE 11. EUROPE NEWBORN SCREENING MARKET, BY ENZYME BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 12. EUROPE NEWBORN SCREENING MARKET, BY DNA BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 13. EUROPE NEWBORN SCREENING MARKET, BY ELECTROPHORESIS, 2019-2027 (IN $ MILLION)
FIGURE 14. EUROPE NEWBORN SCREENING MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 15. PORTER’S FIVE FORCE ANALYSIS
FIGURE 16. KEY BUYING IMPACT ANALYSIS
FIGURE 17. VALUE CHAIN ANALYSIS
FIGURE 18. EUROPE NEWBORN SCREENING MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 19. UNITED KINGDOM NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 20. FRANCE NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 21. ITALY NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 22. RUSSIA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 23. SPAIN NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 24. GERMANY NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 25. REST OF EUROPE NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLIONS)
FIGURE 26. INDUSTRY PLAYER POSITIONING IN 2018 (IN %)

 

List of Tables


TABLE 1. EUROPE NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2. EUROPE INCIDENCE OF CHROMOSOMAL ABNORMALITIES IN NEWBORNS
TABLE 3. INFANT MORTALITY RATE IN DEVELOPING COUNTRIES (TOTAL DEATH/ 1000 LIVE BIRTHS)
TABLE 4. EUROPE NEWBORN SCREENING MARKET, BY PRODUCT, 2019-2027, (IN $ MILLION)
TABLE 5. EUROPE NEWBORN SCREENING MARKET, BY TEST TYPE, 2019-2027, (IN $ MILLION)
TABLE 6. EUROPE NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2019-2027, (IN $ MILLION)
TABLE 7. OPPORTUNITY MATRIX
TABLE 8. VENDOR LANDSCAPE
TABLE 9. REGULATORY FRAMEWORK
TABLE 10. EUROPE NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)
TABLE 11. LIST OF PRODUCT LAUNCHES